Dr. Daniel F. Chueh, M.D.
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,069
Licensed in California since 1990, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
CA license A48624 (first issued 1990; current) -
Child & Adolescent Psychiatry Physician
CA license A48624 (first issued 1990; current) -
Geriatric Psychiatry Physician
CA license A48624 (first issued 1990; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- West Anaheim Medical Center Anaheim, CA
- Foothill Regional Medical Center Tustin, CA
- L A Downtown Medical Center Los Angeles, CA
Medical groups
- Advantage Neuropsychiatric Associates A P C (16 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,069
- Services billed
- 3,432
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,701 | 243 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | 1,328 | 501 |
| Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | 414 | 413 |
| Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | 362 | 75 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 163 | 147 |
| Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | 145 | 31 |
| Psychiatric diagnostic evaluation with medical services | 64 | 63 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 41 | 18 |
| Hospital discharge day management, 30 minutes or less | 33 | 32 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 23 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 102 payments worth $15,440 in total to this clinician.
| Compensation for services other than consulting (speaking, faculty) | $10,041 |
|---|---|
| Food and Beverage | $2,742 |
| Consulting Fee | $2,646 |
| Travel and Lodging | $11.90 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. Mar 30, 2025 | Compensation for services other than consulting (speaking, faculty) UZEDY · Neurology | $5,288 |
| Teva Pharmaceuticals USA, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) UZEDY · Neurology | $2,995 |
| Teva Pharmaceuticals USA, Inc. Oct 14, 2025 | Consulting Fee | $2,646 |
| Otsuka America Pharmaceutical, Inc. Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) REXULTI · PSYCHIATRY | $878 |
| Teva Pharmaceuticals USA, Inc. Nov 30, 2025 | Compensation for services other than consulting (speaking, faculty) UZEDY · Neurology | $529 |
| Otsuka America Pharmaceutical, Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) REXULTI · PSYCHIATRY | $351 |
| Teva Pharmaceuticals USA, Inc. Jun 5, 2025 | Travel and Lodging UZEDY · Neurology · travel to Huntington Beach, CA | $11.90 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $2,321,070 in research payments for these studies, mostly to the institutions running them.
- ITI-007-452
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1…
Boehringer Ingelheim International GmbH - BXCL501401
Bioxcel Therapeutics, Inc. - A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended…
Teva Pharmaceuticals USA, Inc. - A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia
Boehringer Ingelheim International GmbH - Connex-2
Boehringer Ingelheim Pharmaceuticals, Inc. - An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309 - An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X)
Boehringer Ingelheim Pharmaceuticals, Inc. - An Open-Label, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline with Immediate-release Trospium Chloride in Adolescents with Psychiatric Disorders
E.r. Squibb & Sons, L.l.c. - Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.